Angitia’s Latest Megaround to Fuel Mid-Stage Milestones: Venture Report
Angitia Biopharmaceuticals raised a $130 million Series D round, marking its second nine‑digit financing in just over a year after a $120 million Series C and following multiple nine‑figure Series B raises. New investors Frazier Life Sciences and Venrock Healthcare Capital Partners joined existing backers, bringing total recent capital to roughly $250 million. The funding will support Angitia’s three clinical programs—osteoporosis and osteogenesis imperfecta (both in Phase II) and a Phase III spinal fusion candidate—aimed at advancing mid‑stage milestones and de‑risking its pipeline.
A Smarter Way to Watch Biology at Work: Microfluidic Droplet Injector Drastically Cuts Sample Consumption
Researchers at Arizona State University and international partners have unveiled a microfluidic droplet injector that reduces protein sample consumption in X‑ray free‑electron laser (XFEL) experiments by up to 97% while preserving data quality. The device delivers crystal‑laden droplets timed precisely...
White House Launches TrumpRx
The White House unveiled TrumpRx, a new direct‑to‑consumer website that lets Americans compare prescription drug prices and find lower‑cost options. The platform pulls real‑time pricing data from pharmacies, insurers and manufacturers, and provides discount coupons and pharmacy locators. TrumpRx is...
Perspectives on Aging Research and the Near Future of the Field
The blog compiles leading scientists' forecasts for aging research over the next decade, highlighting a shift from descriptive studies to therapeutic interventions. Experts anticipate rapid advances in senescent‑cell clearance, epigenetic reprogramming, multi‑omics profiling, and AI‑driven target discovery. Clinical pipelines are...
STAT+: A Rival Goes After Ocular Therapeutix on Eve of Pivotal Readout on Eye Treatment
Eyepoint Pharmaceuticals' CEO Jay Duker publicly questioned Ocular Therapeutix's wet AMD drug Axpaxli during a Puerto Rico investor conference, alleging the company was withholding negative Phase 3 SOL‑1 results. Ocular is currently in a self‑imposed quiet period ahead of the pivotal...
Teaching Machines to Design Molecular Switches
A multinational French research team applied a Restricted Boltzmann Machine (RBM) to learn the design rules of riboswitch aptamer domains. The generative model created 476 synthetic RNA sequences, some diverging up to 40% from natural examples. High‑throughput SHAPE and DMS...
PolyU Creates Innovative Antibody Against Fat Cell Protein, Paving the Way for New Metabolic Liver Cancer Treatments
Researchers at The Hong Kong Polytechnic University have identified fatty acid‑binding protein 4 (FABP4) as a key adipocyte‑derived factor that fuels metabolic liver cancer. Using proteomics, they linked elevated FABP4 levels to tumor aggressiveness in MASLD‑related hepatocellular carcinoma. The team...
Astrocytes: Brain Disorder Guardians or Troublemakers?
Astrocytes act as metabolic hubs, converting glucose into glycogen, lactate, and neurotransmitter precursors that sustain neuronal firing. In healthy brains they flexibly switch substrates, supporting the glutamate‑glutamine cycle and redox balance. Disease‑linked stressors—such as amyloid‑beta, APOE4, and insulin resistance—drive astrocytes...
This Measles Outbreak at a Detention Center Perfectly Encapsulates America Right Now
Two detainees at the federal family detention center in Dilley, Texas tested positive for measles, prompting the Department of Homeland Security to quarantine contacts and limit movement. The outbreak occurs amid lingering vaccine skepticism and reports of unsanitary conditions within...
#ISC26: Bayer’s Asundexian Reduced Ischemic Strokes by 26% in Phase 3 Trial
Bayer announced that its next‑generation factor XIa inhibitor asundexian cut ischemic stroke incidence by 26% in a pivotal Phase 3 trial for secondary stroke prevention. The study also reported a favorable safety profile, with fewer major bleeding events compared with standard anticoagulants....
Polymer Collapse Unveiled: Water Bridges Tug the Strings
Researchers at Ruhr University Bochum discovered that transient “water bridges” of hydrogen‑bonded water molecules drive the temperature‑induced collapse of the polymer PNIPAM. Using massive molecular‑dynamics simulations and a novel auditory‑analytics (sonification) approach, they visualized billions of time steps and identified...
Boosted Inner Ear Targeting of AAV Vectors Achieved Through Peptide Display on AAV1 Capsid
Researchers have reengineered the AAV1 capsid by displaying short peptide motifs, dramatically improving its ability to target cochlear hair cells and supporting cells. The peptide‑display library yielded variants that achieve up to three‑fold higher transduction efficiency while requiring only a...
Environmental Impact of Pharmaceuticals: A Global Challenge Unveiled
A new global report highlights the escalating environmental threat posed by pharmaceutical residues in water bodies, soils, and wildlife. Researchers found detectable levels of active drug compounds in rivers across North America, Europe, and Asia, often exceeding safety thresholds. The...
CRISPR-Based Biosensors Enable Real-Time Ocean Health Monitoring
Researchers at Harvard's Wyss Institute and MIT have created a low‑cost, field‑deployable CRISPR‑Cas12a biosensor that detects DNA or RNA from key marine barometer species in about 40 minutes. The platform integrates a lateral‑flow strip for instrument‑free visual readout and a...
Hims & Hers Copies Novo Nordisk's New Wegovy Pill
Telehealth firm Hims & Hers has launched an oral semaglutide pill priced at $49 per month, directly copying Novo Nordisk’s newly released oral Wegovy that sells for $149. Novo reports strong uptake of its product, with roughly 50,000 prescriptions filled...
BMS Beats Again Despite Eliquis and Cobenfy Disappointments
Bristol Myers Squibb posted fourth‑quarter 2025 sales of $12.5 billion, topping the $12.28 billion consensus. Eliquis generated $3.4 billion, falling short of expectations, while the new schizophrenia drug Cobenfy earned $51 million, missing forecasts by 3 %. Despite the miss, BMS forecasts 10‑15 % Eliquis growth...
Strengthening Foundations: Reflections on 2025 and What's Ahead for 2026
Addgene closed 2025 by supporting researchers in 112 countries, highlighted by a rapid plasmid shipment to Laos. The nonprofit welcomed over 500 new depositing labs and its materials featured in 9,000 publications last year. New tools such as a Developer’s...
WEF Welcomes ACG Shirwal as First Pharma Packaging Site in Global Lighthouse Network
The World Economic Forum has added ACG’s Shirwal facility to its Global Lighthouse Network, making it the first pharmaceutical packaging site to receive the honor. The plant leverages AI, machine learning, IoT and digital twins to slash defects by 71%...
Bristol Myers Draws Pipeline Excitement as Several Data Readouts Near
Bristol Myers Squibb highlighted at least ten late‑stage data readouts slated for 2024, reigniting investor enthusiasm after a period of muted pipeline news. The readouts span oncology, immunology and rare disease programs, many of which could support new label extensions...
GLP-1s and the Super Bowl
Hims & Hers launched a new Super Bowl commercial promoting GLP‑1 weight‑loss drugs, positioning the brand amid a surge in public interest. The ad directly calls out disparities in healthcare access, contrasting affluent consumers’ ability to afford the medication with...
Rare Brain Toxicity Observed in Cancer Patients Undergoing 5-FU Chemotherapy
A case report published in Oncoscience documents a rare instance of hyperammonemic encephalopathy triggered by 5‑fluorouracil (5‑FU) in a 63‑year‑old pancreatic‑cancer patient. Despite normal liver function tests, serum ammonia spiked during chemotherapy cycles, causing acute confusion and lethargy. Prompt discontinuation...
DNA Offers a Breakthrough Solution to the Global Data Storage Challenge
Researchers at Arizona State University’s Biodesign Institute have demonstrated a DNA‑nanotechnology platform that stores and encrypts data using three‑dimensional molecular shapes, read electrically via micro‑sensors and decoded with AI. This approach bypasses traditional sequencing, delivering ultra‑dense, chemically stable storage and...
Thermo Fisher, Charles River Workforce Cuts; WuXi Signs Contract with Vertex
Thermo Fisher Scientific announced the closure of its chemical analysis manufacturing site in Franklin, Massachusetts, citing current customer demand shifts. The shutdown will affect the plant’s workforce, adding to a wave of staffing reductions across the life‑science services sector, including...
Liver-Produced Protein Identified as Essential for Men’s Bone Health, New Study Finds
A McGill University study published in Matrix Biology identifies plasma fibronectin, a liver‑produced protein, as a critical regulator of bone formation in male mice. Mice lacking hepatic fibronectin show marked reductions in trabecular bone mass, while female mice are unaffected,...
Telehealth Provider Hims Goes After Novo's Weight Loss Pill with Compounded Version
Hims & Hers announced it will begin selling a compounded version of Novo Nordisk's Wegovy weight‑loss injection on Thursday, just weeks after the FDA approved the brand‑name drug. The telehealth firm positions the lower‑cost alternative as a more accessible option...
Quantum Computing Speeds up Genome Mapping, Unlocking Faster Disease Diagnosis
Researchers from IIT and IBM have unveiled a hybrid quantum‑classical workflow that accelerates de novo genome assembly by reformulating Hamiltonian and Eulerian path problems as a Higher‑Order Binary Optimisation (HOBO) task solved with the Variational Quantum Eigensolver (VQE). The approach integrates...
Negatively Charged Carbon Dot‐Linked Glycyrrhizic Acid Hydrogel Promoted Hemostasis, Immunoregulation and Re‐Epithelialization of Wound Closure
The study introduces a charred Trachyparcus‑derived carbon dot (CT‑CD) linked glycyrrhizic acid (GA) hydrogel, termed CT@GA‑gel, that forms at GA concentrations below 0.5 %. The negative surface charge of CT‑CDs enables low‑dose crosslinking, yielding an injectable, self‑healing, and adhesive dressing. Enhanced...
Eisai Gains Henlius Therapy; LB Pharma Snags $100M in Funding
Eisai announced an exclusive commercial license with China’s Henlius to sell the anti‑PD‑1 antibody serplulimab in Japan. The agreement gives Eisai sole rights to market the immunotherapy, positioning it alongside the company’s existing oncology portfolio. Serplulimab, a checkpoint inhibitor, is...
LimbLab: A Tool to Visualize Embryonic Development in 3D
LimbLab is an open‑source pipeline created by EMBL Barcelona to visualise and analyse three‑dimensional embryonic limb‑bud data. The workflow cleans raw microscopy volumes, builds computational meshes, assigns developmental age, aligns samples to reference models and logs each step for reproducibility....
Solid Foundations Beat AI Hype in Bioinformatics
1/ AI won’t save sloppy science. Before you dive into deep learning, master your foundations. Here’s why basic bioinformatics still rules 🧵 https://t.co/nPbaEK3hGf
The Bioelectric Tech Stack
The episode frames biomanufacturing as a layer of the emerging electric tech stack, arguing that biology will become the chemical manufacturing layer that converts cheap electricity and feedstocks into high‑value molecules. It contrasts China’s systematic investment in the physical infrastructure—feedstock...
Prolonged PDA Exposure Raises Late Kidney Injury Risk
A multicenter study published in the Journal of Perinatology finds that prolonged exposure to patent ductus arteriosus (PDA) significantly increases the risk of late‑onset acute kidney injury (AKI) in infants born before 28 weeks gestation. Researchers tracked PDA duration and...
Unveiling the Clinical Significance of Unique Brain Functional Connectomes in Major Depressive Disorder
Researchers from Chiba University and partner institutions reported that functional connectome (FC) uniqueness—a measure of individual brain connectivity patterns—is markedly reduced in patients with Major Depressive Disorder (MDD). The study, using harmonized resting‑state fMRI across multiple sites, found the greatest...
Breakthrough Stem Cell Therapy Shows Promise for Parkinson’s Disease
Researchers at USC's Keck Medicine have launched a Phase 1 trial implanting iPSC‑derived dopaminergic neurons to treat moderate‑to‑severe Parkinson's disease. The therapy, using Kenai Therapeutics' RNDP‑001 product, is administered via stereotactic surgery into the basal ganglia of twelve participants. The FDA...
Revolutionary Low-Temperature Activation Enables Deployment of Smart 4D-Printed Vascular Stents
Researchers from Japan and China have created a 4D‑printed vascular stent that self‑expands at body temperature, eliminating the need for external heating. The device uses a polycaprolactone‑based shape‑memory polymer composite tuned to a 37 °C transition with diethyl phthalate as a...
Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy
Novartis announced the removal of six Phase 1 oncology candidates—including KFA115, HRO761, MGY825, and AAA802—from its pipeline and introduced two new Phase 1 assets, AMO959 for prostate cancer and GCJ904 for solid tumors. The reshuffle aligns with a strategic review aimed at...
Commentary Urges Balance Between Research Integrity and Technology Transfer in Biomedicine
Virginia Tech professor Robert Gourdie published a commentary in Nature Biotechnology urging policymakers to balance research integrity with a robust technology‑transfer system. He warns that overly restrictive oversight could weaken the U.S. pipeline that moves publicly funded discoveries into commercial therapies....
Fluorescent Paper Test Revolutionizes Blood Typing, Antibody Detection
Researchers have introduced a paper‑based fluorescent assay that uses bioengineered red blood cells stable at room temperature to perform blood typing and antibody titer measurement. The assay combines fluorescent tagging with capillary flow on paper, delivering sensitivity and specificity above...
Sildenafil’s Variable Impact on Preemie Lung Hypertension
A recent multicenter study examined sildenafil’s effectiveness in treating pulmonary hypertension among preterm infants. The findings revealed that while some neonates experienced improved oxygenation and reduced pulmonary pressures, others showed minimal benefit or adverse hemodynamic effects. Efficacy appeared linked to...
ApexOnco IPO Highlights Valuation Benchmarks for Biotech
$EIKN prices at $18/share, to raise $381m at a $972m market cap. Here's @ApexOnco on what this IPO tells us: https://t.co/OYpmTI21qI
Programmable RNA 2.0: Beyond the First mRNA Revolution
BioSpace’s Denatureed podcast episode "Programmable RNA 2.0" spotlights the next wave of RNA therapeutics beyond the COVID‑19 mRNA vaccine success. Host Jennifer Smith‑Parker interviews Erik Digman Wiklund of Circio and Jacob Becraft of Strand Therapeutics about emerging platforms such as circular RNA...
INBRAIN’s “Rice‑sized” Graphene BCI Chip Marks New Phase in Merck Collaboration
INBRAIN Neuroelectronics announced a new rice-sized graphene BCI chip as part of its ongoing partnership with Merck. The bidirectional chip can record and stimulate neural activity, using AI-driven algorithms to decode speech signals and deliver closed-loop stimulation. Merck is shifting...
A 3D-Printed Delivery System Enhances Vaccine Delivery via Microneedle Array Patch
Researchers at the University of Tokyo used 3D‑printing to add a pillar‑backed layer to microneedle array patches (MAPs), preserving more live virus during fabrication. The pillar‑guided MAPs showed higher viral titers and induced protective immunity against SARS‑CoV‑2 in mice. This...
Reviewing Social Determinants in Neonatal Clinical Trials
A systematic review in the Journal of Perinatology reveals that neonatal clinical trials largely omit detailed social determinants of health (SDOH) data, with race and ethnicity reported far more often than income, education, or neighborhood factors. The analysis of dozens...
Grail Multi-Cancer Test Taps Into Hims & Hers Network
Grail has partnered with telehealth firm Hims & Hers to sell its Galleri multi‑cancer blood test at a $250 discount off the $949 list price. The collaboration follows Grail’s recent filing for FDA pre‑market approval, based on interim results from...
Connect More
Veeva Systems’ Aaron Bean outlines five connected engagement models for biopharma, from strategic account management to marketing‑centric approaches, to address mounting access challenges in the UK and Europe. He highlights that HCP accessibility in the UK is only 25% versus...
Sex Differences in Atherosclerotic Cardiovascular Disease
A new analysis of the CARDIA cohort spanning 34 years confirms that men experience premature atherosclerotic cardiovascular disease (CVD) several years earlier than women, with a 5% cumulative incidence occurring at age 50.5 versus 57.5 for women. The gap emerges...
Α-Ketoglutarate Interacts with TET to Regulate Cellular Senescence
A recent human trial of α‑ketoglutarate (AKG) supplementation failed to demonstrate measurable health benefits, prompting renewed focus on pre‑clinical evidence. New cell‑based research shows that the AKG‑TET enzymatic axis governs epigenetic reprogramming that drives or reverses cellular senescence. Down‑regulating AKG...
Abbott's Wireless Heart Failure Sensor Cleared for NHS Use
Abbott’s CardioMEMS HF wireless sensor has received NICE approval for routine NHS use in chronic heart‑failure patients. The tiny implant measures pulmonary artery pressure and transmits daily readings via a pillow‑embedded antenna, allowing clinicians to adjust medication remotely. Clinical trials...
Mitophagy’s Role in Pancreatic Cancer Therapy
Recent research highlights mitophagy—a cellular recycling process—as a promising lever in pancreatic cancer treatment. Activating the PINK1‑PARK2 pathway triggers selective mitochondrial clearance, making tumor cells more vulnerable to chemotherapy and immunotherapy. Pre‑clinical models show that combining mitophagy inducers with standard...